1.Polymyositis after Pegylated Interferon Therapy for Hepatitis C.
Shi Nae KIM ; Seung Min HAN ; Joong Hyun PARK ; Jeong Yeon KIM ; Jae Hyeon PARK
Journal of the Korean Neurological Association 2014;32(4):342-344
No abstract available.
Hepatitis C*
;
Interferons*
;
Polymyositis*
2.Endogenous interferon ?alpha)/?beta) produced by lipid A-stimulated macrophages enganced phagocytic activity of mouse macrophages.
Korean Journal of Immunology 1993;15(2):147-153
No abstract available.
Animals
;
Interferons*
;
Macrophages*
;
Mice*
3.Lamivudine and interferon combination therapy in chronic type B hepatitis.
Korean Journal of Medicine 2004;66(2):105-107
No abstract available.
Hepatitis*
;
Interferons*
;
Lamivudine*
4.Lamivudine and interferon combination therapy in chronic type B hepatitis.
Korean Journal of Medicine 2003;65(6):629-630
No abstract availalbe.
Hepatitis*
;
Interferons*
;
Lamivudine*
5.The Mechanisms of Interferon - alpha and Interferon - gamma Induced Antiviral Activity in Peritoneal Macrophages.
Suh Neung PYO ; Jae Hag LEE ; Dong Kwon RHEE
Korean Journal of Immunology 1997;19(3):307-312
No abstract available.
Interferons*
;
Macrophages
;
Macrophages, Peritoneal*
6.Lamivudine and interferon combination therapy in chronic type B hepatitis.
Korean Journal of Medicine 2004;66(1):1-3
No abstract availalbe.
Hepatitis*
;
Interferons*
;
Lamivudine*
7.Psoriasis and Hepatitis C: Improvement with Interferon.
Eyassu HABTE-GABR ; Nicolas LECEA
Annals of Dermatology 2011;23(Suppl 3):S411-S413
No abstract available.
Hepatitis
;
Interferons
;
Psoriasis
8.Interferons 50 years and liver diseases.
Chinese Journal of Hepatology 2007;15(11):801-803
9.Molecular Biological Analysis of the Collagen Changes by Interferon Gamma Following Partial Unilateral Ureteral Obstruction.
Kwang Myung KIM ; Yong Tae KIM ; Jung Yun JUNG ; Hae Il CHEONG ; Wun Jae KIM ; Si Whang KIM
Korean Journal of Urology 2000;41(12):1451-1458
No abstract available.
Collagen*
;
Interferons*
;
Ureter*
;
Ureteral Obstruction*
10.Combination Therapy with Intralesional Interferon α-2b and Pulsed Dye Laser for the Treatment of Periungual Warts.
Gwang Seong CHOI ; Jeong Hun PARK ; Young Keun KIM ; Gwang Seong CHOI
Annals of Dermatology 2002;14(2):82-87
BACKGROUND: Periungual warts are a therapeutic challenge. Many studies have revealed that intralesional interferon α-2b therapy and pulsed dye laser therapy have numerous advantages over other modalities of theratment. OBJECTIVE: The purpose of this study was to determine if combination therapy with intralesional interferon α-2b and pulsed dye laser might offer an effective treatment for periungual warts. METHODS: Thirty-three patients were randomly assigned to one of three study groups. In group A, the patients received both intralesional interferon α-2b treatment and pulsed dye laser(PDL) therapy (n=13). Group B patients were treated wit intralesional interferon α-2b alone (n=10) and group C was done with PDL therapy only (n=10). RESULTS: The clearance rate was 92.3% for the patients treated with the combination therapy of intralesional interferon α-2b treatment and pulsed dye laser (PDL) therapy. It was 50% for the patients with the intralesional interferon α-2b treatment alone, and 0% for the group with the PDL therpy only. No significant side effects were observed. At 6 months after cessation of the therapy, total 2 cases (one from group A and the other from group B) were recurred. CONCLUSION: The combination therapy with intralesional interferon α-2b treatment and pulsed dye laser therapy was highly effective for the treatment of recalcitrant periungual warts.
Humans
;
Interferons*
;
Lasers, Dye*
;
Warts*
Result Analysis
Print
Save
E-mail